The KEYNOTE-590 trial found that combining pembrolizumab with chemotherapy for patients with advanced esophageal cancer led to improved overall survival compared to chemotherapy alone. This was especially true for patients with high expression of PD-L1, the target of pembrolizumab. The study included patients with esophageal squamous cell carcinoma, esophageal adenocarcinoma, and esophagogastric junction adenocarcinoma. The findings suggest that adding pembrolizumab to standard chemotherapy regimens could be an effective treatment option for previously untreated advanced esophageal cancer patients.
Source link
Pembrolizumab Improves OS in Esophageal Cancer
